| Creatine vs Kazuya | 25–16 | 60.98% |
| Creatine vs King | 24–12 | 66.67% |
| Creatine vs Bryan | 15–18 | 45.45% |
| Creatine vs Hwoarang | 16–16 | 50.00% |
| Creatine vs Jin | 19–11 | 63.33% |
| Creatine vs Reina | 18–11 | 62.07% |
| Creatine vs Steve | 15–13 | 53.57% |
| Creatine vs Lili | 7–15 | 31.82% |
| Creatine vs Dragunov | 11–11 | 50.00% |
| Creatine vs Nina | 11–9 | 55.00% |
| Creatine vs Leroy | 12–8 | 60.00% |
| Creatine vs Jack-8 | 4–14 | 22.22% |
| Creatine vs Law | 14–3 | 82.35% |
| Creatine vs Paul | 12–4 | 75.00% |
| Creatine vs Lee | 12–4 | 75.00% |
| Creatine vs Claudio | 10–5 | 66.67% |
| Creatine vs Eddy | 7–8 | 46.67% |
| Creatine vs Yoshimitsu | 3–10 | 23.08% |
| Creatine vs Xiaoyu | 8–5 | 61.54% |
| Creatine vs Asuka | 5–8 | 38.46% |
| Creatine vs Feng | 6–7 | 46.15% |
| Creatine vs Kuma | 7–6 | 53.85% |
| Creatine vs Zafina | 7–6 | 53.85% |
| Creatine vs Azucena | 7–6 | 53.85% |
| Creatine vs Heihachi | 5–8 | 38.46% |
| Creatine vs Jun | 8–4 | 66.67% |
| Creatine vs Victor | 9–3 | 75.00% |
| Creatine vs Lars | 6–4 | 60.00% |
| Creatine vs Raven | 5–5 | 50.00% |
| Creatine vs Lidia | 6–4 | 60.00% |
| Creatine vs Devil Jin | 5–4 | 55.56% |
| Creatine vs Alisa | 6–3 | 66.67% |
| Creatine vs Leo | 8–0 | 100.00% |
| Creatine vs Clive | 2–5 | 28.57% |
| Creatine vs Shaheen | 2–0 | 100.00% |
| Creatine vs Panda | 0–2 | 0.00% |
Limitations
This data is often requested to give insight into which characters you have more trouble with than others, but it is not particularly helpful for that. The main issue is that it is heavily skewed by how strong the opponents you play are.
For example, this data suggests my worst matchup is clearly vs Reina, but that's just because most of those games are vs Yagami.
There is a way to account for this being worked on. The central idea is to assign each matchup a rating vs you which adjusts based on the result, much like the regular rating but also based on the rating of each player. With this, it would give a better summary of how well you perform vs each character.
In the meantime, this page is here to present the data as requested.